retatrutide shot A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Trials Retatrutide Helped Adults With Obesity

Malignant melanoma pertains to an aggressive skin tumor with poor prognosis, with approximately 50% of patients harboring gain-of-function mutations in the BRAF gene

GLP-1 receptor agonists are a class of prescription medications originally developed for type 2 diabetes and now clinically recognised for their ability to support weight management in appropriate patients

Retatrutide is an investigational triple-agonist (GLP-1, GIP, and glucagon) with a half-life of roughly 6 days (Coskun et al., Cell Metabolism, 2022)

GLP-1 agonists can help lower inflammation, a common lipedema issue, by improving metabolic health and reducing adipose tissue

When starting retatrutide, its common to experience reduced appetite, feeling full sooner, and mild digestive changes

Published online November 1, 2023